Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Clinical trial NCT05117008 · TERMINATED

Trial details

NCT number

NCT05117008

Sponsor

Medical College of Wisconsin

Status

TERMINATED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2022-07-19

Primary completion

2024-01-15

Enrollment

1

View on ClinicalTrials.gov